73rd Conference on Mass Spectrometry and Allied Topics
Baltimore, MD, USA
June 1–5, 2025
Meet Genedata Experts at ASMS 2025.
Don't miss the opportunity to meet our experts at booth #354 and see how Genedata solutions efficiently support the whole biopharmaceutical R&D workflow, including screening and protein engineering, expression and purification, characterization and analysis of protein therapeutics, cell line design and development, bioprocess optimization, and quality control of biologicals. You will also have the opportunity to engage with our partner companies — SCIEX, Beckman Life Sciences, and Phenomenex.
Recommended Talk
Novartis
Characterizing O-Glycosylation in the Hinge Region of Immunoglobulin a by Bottom-Up and Middle-Up MS with Electron Activated Dissociation
Jonathan Dhenin, Novartis Pharma AG, Basel, Switzerland
Tuesday June 3 | 9:10 am-9:30am | Eastern I Hall AB
Recommended Posters
Genedata
Enhancing Analysis Efficiency in High-Throughput Semi-Targeted Intact Mass Spectrometry
Juan Florez, Genedata, Basel, Switzerland
Poster #235
Genedata
Strategies for Rapid Intact Mass Screening Analysis: Achieving One-Second per Well
Matthew Green, Genedata Ltd., Cambridge, UK
Poster #236
Genedata
Higher Throughput Peptide Mapping Workflows Enabled by Automation of MS Data Analysis, Review, and Reporting
Stephen Kok, Genedata Inc., San Francisco, CA, USA
Poster #239
Genedata
Fully Automated Candidate Creation Workflow for Intact Mass Mapping of Oligonucleotide Therapeutics
Michelle English, Genedata Inc., Boston, MA, USA
Poster #498
Corteva Agriscience & Genedata
Hydrophobic Interaction Liquid Chromatography Untargeted Plant Metabolomics for Soybean Amino Acid Pathway Analysis
Brian M. Ruddy, Corteva Agriscience, Johnston, IA, USA
Poster #564
Novartis & Genedata
A Robust And Versatile New Peak Detection Workflow to Facilitate the Multi-Attribute Method (MAM) Implementation From Research to Commercialization
Francois Griaud, Novartis Pharma AG, Basel, Switzerland
Poster #608
Pfizer
From Automated Covalent Hit Finding to Characterizing Target Protein Covalent Modifiers
Yecenia Peraza, Pfizer, San Diego, CA, USA
Poster #397
AstraZeneca
From Complexity to Clarity: Automating Multi-Layered Targeted Proteomics Data Analysis
Uthpala I Seneviratne, AstraZeneca, Waltham, MA, USA
Poster #738
EMD Serono
The Missing Step to Perform MAM in QC
Julien Bourquin, EMD Serono, Corsier-sur-Vevey, Switzerland
Poster #004
Johnson & Johnson
High Throughput Peptide Mapping Pipeline to Support Early PTM Liability Assessments of Biologics
John Patrick, Johnson and Johnson Innovative Medicine, Spring House, PA, USA
Poster #027
Johnson & Johnson
Mass Spectrometry Footprinting of the Membrane Protein Therapeutic Target GRPC5D
Mengqi Chai, Johnson and Johnson Innovative Medicine, Spring House, PA, USA
Poster #572
AstraZeneca
Accelerating cyclic peptide hit optimisation using a novel affinity-selection mass spectrometry (ASMS) platform
Poppy Llowarch, AstraZeneca, Cambridge, UK
Poster #242
Novartis
Inducing Disulfide Scrambling to Confidently Identify Low-Abundance Scrambles: Could a Forced-Scrambling Assessment Benefit Disulfide Engineered Biotherapeutics?
David R Bush, Novartis Biomedical Research Inc., Cambridge, MA, USA
Poster #604
